Generic Tapentadol ER
Pain Management
Key Facts
About Hikma Pharmaceuticals
Hikma Pharmaceuticals is a revenue-generating, publicly traded pharmaceutical company with a mission to improve global access to high-quality medicines. It operates through three distinct, market-leading segments: a top-five global Injectables business, a rapidly growing US-focused Generics (Hikma Rx) division, and a Branded business that is the largest pharmaceutical company by sales in the MENA region. The company's strategy focuses on striving for operational excellence, diversifying its product pipeline, and empowering its people, supported by a culture of innovation, caring, and collaboration. Recent achievements include launching 84 products in 2025 and implementing strategic investments to drive future growth.
View full company profileTherapeutic Areas
Other Pain Management Drugs
| Drug | Company | Phase |
|---|---|---|
| Authorized Generic of Nucynta® ER (tapentadol) | Hikma | Launched |
| Authorized Generic of Nucynta® (tapentadol) | Hikma | Launched |
| Intradermal Microneedle Patch | Isosceles Pharmaceuticals | Pre-clinical |
| Non-addictive poppy-derived analgesic | Emerzene | Pre-clinical |
| Pain R&D | Orion Pharma | Not Specified |
| LymphaTouch Device | Lymphatouch | Commercial |
| Generic Oxycodone ER (Oxycontin) | Natco Pharma | Launched |
| Generic Tapentadol | Hikma Pharmaceuticals | Approved |